Alan Carr
Analyst at Needham
Ticker Coverage
Sector Coverage
Mentions in the News
Is CRISPR Therapeutics a Buy?
With its head start in the emerging gene-editing market, does CRISPR deserve investors' money more than its rivals do?
Published: Sep 25 2019
3 Biotech Stocks Surging on Positive Results
It’s no question that the biotech space is booming. According to Global Market Insights, the global biotech market is expected to reach $775 billion by 2024, up from $399.4 billion in 2017. While they tend to be more volatile, biotech stocks can offer substan…
Published: Sep 23 2019
Moderna Gets 3% Stock Boost From Early Clinical Data
Moderna shared interim data from two phase one clinical trials today, leading to a bump in its stock price.
Published: Sep 13 2019
Would you like to be included in the directory? Let us know!
© Street Contxt. All Rights Reserved.